Zanzalintinib plus atezolizumab improves survival in refractory mCRC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC

Low-dose pembrolizumab plus neoadjuvant chemo option for TNBC in resource-constrained settings

Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC

Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer

Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Enhancing breast cancer care through AI and collaboration

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer